Membrane‐anchored growth factors, the epidermal growth factor family: Beyond receptor ligands
- 6 February 2008
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 99 (2), 214-220
- https://doi.org/10.1111/j.1349-7006.2007.00676.x
Abstract
The epidermal growth factor (EGF) family and the EGF receptor (EGFR, ErbB) tyrosine kinase family have been spearheading the studies of signal transduction events that determine cell fate and behavior in vitro and in vivo. The EGFR family and their signaling pathways are giving us tremendous advantages in developing fascinating molecular target strategies for cancer therapy. Currently, two important types of EGFR inhibitors are in clinical use: neutralizing antibodies of EGFR or ErbB2, and synthetic small compounds of tyrosine kinase inhibitors designed for receptors. On the other hand, basic research of the EGF family ligands presents new challenges as membrane-anchored growth factors. All members of the EGF family have important roles in development and diseases and are shed from the plasma membrane by metalloproteases. The ectodomain shedding of the ligands has emerged as a critical component in the functional transactivation of EGFRs in interreceptor cross-talk in response to various shedding stimulants such as G-protein coupled receptor agonists, growth factors, cytokines, and various physicochemical stresses. Among the EGFR-ligands, heparin-binding EGF-like growth factor (HB-EGF) is a prominent ligand in our understanding of the pathophysiological roles of ectodomain shedding in cancer, wound healing, cardiac diseases, etc. Here we focus on ectodomain shedding of the EGF family ligands, especially HB-EGF by disintegrin and metalloproteases, which are not only key events of receptor cross talk, but also novel intercellular signaling by their carboxy-terminal fragments to regulate gene expression directly.This publication has 100 references indexed in Scilit:
- An intermediary role of proHB-EGF shedding in growth factor-inducedc-Myc gene expressionJournal of Cellular Physiology, 2007
- ADAMs in cancer cell proliferation and progressionCancer Science, 2007
- Substrate Selectivity of Epidermal Growth Factor-Receptor Ligand Sheddases and their Regulation by Phorbol Esters and Calcium InfluxMolecular Biology of the Cell, 2007
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Deregulated Bag‐1 protein expression in human oral squamous cell carcinomas and lymph node metastasesThe Journal of Pathology, 2002
- Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin AOncogene, 1999